Welcome to LookChem.com Sign In|Join Free
  • or
Benzenamine, 4-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

866357-72-4

Post Buying Request

866357-72-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

866357-72-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 866357-72-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,6,3,5 and 7 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 866357-72:
(8*8)+(7*6)+(6*6)+(5*3)+(4*5)+(3*7)+(2*7)+(1*2)=214
214 % 10 = 4
So 866357-72-4 is a valid CAS Registry Number.

866357-72-4Downstream Products

866357-72-4Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins

Li, Ze,Khaliq, Mansoora,Zhou, Zhigang,Post, Carol Beth,Kuhn, Richard J.,Cushman, Mark

supporting information; experimental part, p. 4660 - 4671 (2009/07/11)

Flavivirus envelope proteins (E proteins) have been shown to play a pivotal role in virus assembly, morphogenesis, and infection of host cells. Inhibition of flavivirus infection of a host cell by means of a small molecule envelope protein antagonist is an attractive strategy for the development of antiviral agents. Virtual screening of the NCI chemical database using the dengue virus envelope protein structure revealed several hypothetical hit compounds. Bioassay results identified a class of thiazole compounds with antiviral potency in cell-based assays. Modification of these lead compounds led to a series of analogues with improved antiviral activity and decreased cytotoxicity. The most active compounds 11 and 36 were effective in the low micromolar concentration range in a cellular assay system.

SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS

-

Page/Page column 130, (2010/02/14)

The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 866357-72-4